Table 2 Assessments, treatments, and course of the disease during the PICU stay

Radiological assesment

 Ultrasound

21 (42%)

 CT scan

22 (44%)

 MRI

7 (14%)

Identified bacteria

43 (86%)

 Only one micro-organism/two or more micro-organisms

36 (72%)/7 (14%)

Gram positive

40 (91%)

 Staphylococcus aureus

17 (39%)

  Methicillin-sensitive

15 (88%)

  Panton valentine Leukocidin

15 (88%)

  Toxic shock syndrome toxin

10 (59%)

 Group A β-hemolytic Streptococcus

14 (32%)

Gram negative

12 (25%)

 Escherichia coli

5 (11%)

 Pseudomonas aeruginosa

4 (9%)

General treatments in the PICU

 Mechanical ventilation/duration (days)

29 (58%)/3 (2; 3)

 Fluid expansion/volume (mL/kg)

35 (70%)/37.5 (22.8; 65)

 Vasopressors/duration (days)

27 (54%)/3 (2; 3)

 Morphine/duration (days)

43 (86%)/5 (4; 10.5)

 Benzodiazepine/duration (days)

33 (66%)/5.5 (2; 9)

 Transfusion of blood products

25 (50%)

 Transfusion of albumin

25 (50%)

Specific treatments

 Surgery/time since admission (days)

34 (68%)/1 (1; 5)

 One surgical procedure

15 (44%)

 Multiple surgical procedures/median per patient

19 (56%)/3.5 (2; 5)

 Amputation

0

 Antitoxin antibiotics

42 (84%)

 Immunoglobulins/doses (g/kg)^a

18 (36%)/2 (2; 2)

 Hyperbaric oxygen

5 (10%)

On PICU discharge

 Deep thrombosis

6 (12%)

 Nosocomial infections

12 (24%) during 4 stays

 In-hospital death/day of death

3 (6%)—D7, D9, and D13

 POPC (without the 3 deaths)

1.7 ± 0.9

 In-PICU length of stay (days)

12.5 ± 14.5; 8 (5; 14)

 In-hospital length of stay (days)

35.6 ± 42; 21 (12.5; 41.8)